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Abstract
Ether--go-go-1 (Eag1) is a CNS-localized voltage-gated potassium channel
that is found ectopically expressed in a majority of extra-cranial solid tu-
mors. While circumstantial evidence linking Eag1 to tumor biology has
been well established, the mechanisms by which the channel contributes to
tumor progression has until recently remained elusive.
In this study, we have used in vivo and in vitro techniques to identify Eag1
interactions with HIF-1 regulatory system as a candidate mechanism. Eag1
functionally and physically interacts with HIF prolyl hydoxylases (PHD)
and immunoprecipitates with ubiquitin and pVHL. Eag1 ubiquitin immuno-
precipitation is PHD dependent, and Eag1 undergoes proteasomal degra-
dation. Eag1 expression stabilizes HIF and promotes VEGF secretion and
angiogenesis in vivo.
Our data suggest that Eag1 interferes with the cellular mechanism for main-
taining oxygen homeostasis, increasing HIF-1 activity, and thereby VEGF
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The eag ion channel family is an important class of potassium-permeant ion channels
that includes members of the eag, erg, and elk sub-families (1). As the founding
member of this family (2; 3), Eag1 has been studied for its role in both excitable and
non-excitable cells. Eag1 expression is largely restricted to the central nervous system,
where widespread mRNA (4; 5) and protein (6) expression is found.
1.1.1 Eag1 structure
As a potassium ion channel, Eag1 shares certain homologies with other potassium chan-
nels. It is composed of a tetramer with each subunit consisting of an amino terminus,
6 transmembrane segments (S1-S6, including the voltage sensor S4), a pore region, and
carboxy terminus (Figure 1.1). Eag1 is distinct in both the size of the N-terminus ( 200
amino acids) and the C-terminus ( 500 amino acids) as well as the distinct ”Cole-Moore
shift” (7) it exhibits. Within the C-terminus is found a tetrameric coiled coil domain
(TCC) (8), which induces very strong intra-subunit binding and is likely a key factor
in channel assembly.
Eag1 has many candidate interaction domains as determined by homology, including
PKA, PKC, CaMK2, cyclic nucleotide binding domain (cNBD), a nuclear localization
signal (NLS), and a calmodulin binding domain (CaM). The C-terminus in particu-
lar has extensive putative binding domains, and several binding partners have been
identified to modulate Eag1 activity by binding to the C-terminus.
1
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Figure 1.1: Structure of Eag1 protein - Eag1 has an extensive pore region located
between S5 and S6 transmembrane segments and a very large N- and C- terminus. PAS:
Per-Arnt-Sim domain, cNBD: cyclic nucleotide binding domain, NLS: Nuclear localiza-
tion signal, CaM: Calmodulin binding domain, TCC: tetrameric coiled coil domain, PKA:
protein kinase A, PKC: protein kinase C, CaMKII: calmodulin-dependent kinase 2 domain.
1.1.2 Eag1 binding partners and modulators
One of the most notable and unique identifiers of Eag1 is the pronounced ”Cole-Moore
shift”(7) it exhibits, in which the kinetics of activation are dependent on the pre-pulse
potential. In the case of Eag1, the Cole-Moore shift is extremely pronounced, causing
an activation delay of 100s of milliseconds after a 20mV change of the conditioning pulse
(9). This shift is dependent not only on pre-pulse potential, but also on extracellular
Mg2+ (10). Mg2+ binds to the extracellular hydrophilic loop between S2 and S3 and
slows channel gating (11).
Eag1 current is also blocked by intracellular Ca2+ (12) which occurs through a
calmodulin dependent mechanism. Activated calmodulin binds to both the amino- and
carboxy-termini (13; 14) and inhibits Eag1 current, perhaps by sterically preventing
channel opening. It was also observed that calmodulin-dependent kinase 2 (CamK2)
binds and phosphorylates Eag1 in Drosophilia through an unrelated pathway (15),
providing an alternate candidate mechanism for Ca2+ block of Eag1. To complicate
matters further, Eag1 has been shown to interact with Camguk/CASK adapter protein
(16), which also interacts with CamK2.
2
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Finally, epsin co-expression with Eag1 in HEK293 cells shows a slowing of channel
activation in physiologically relevant voltage ranges (17). Epsin has been implicated in
endocytosis and is expressed in synaptic terminals, where Eag1 is also found. Eag1 is
also affected by cytoskeletal interactions, as actin filament disruption increases current
density in transfected CHO cells while microtubule disruption reduces current density
(18). Moreover, Eag1 is expressed during myoblast fusion (19), a process that requires
extensive cytoskeletal remodeling.
1.1.3 Eag1 and cell proliferation
One of the most curious and compelling consequences of Eag1 expression arose after
the identification of its role in the cell cycle and cellular proliferation. Eag1 current in
Xenopus oocytes was found reduced during the maturation phase, a phenomenon that
could be reproduced by co-injection of mitosis-promoting factor (20).
Eag1 expression was also discovered to induce a transformed phenotype in trans-
fected cells, characterized by a loss of dependence on growth factors and in a loss of
contact inhibition (21). Moreover, inhibition of Eag1 expression using both antisense
oligonucleotides and siRNA (22) has been found to reduce cellular proliferation. In-
hibiting Eag1 using the open channel blockers astemizole or imipramine also reduces
cell proliferation in vitro (23; 24).
Finally, blocking Eag1 permeation by treatment with a pore-directed antibody was
found to inhibit cellular proliferation in both heterologous and natively expressing cells
(25).
1.1.4 Eag1 and cancer
Cancer causes approximately 13% of all deaths worldwide (26) and 25% of deaths in
industrialized countries. As a disease that primarily afflicts older people, this fraction
of deaths caused is expected to increase as lifespan continues to increase. By 2020, the
number of new cancer cases is expected to grow by 50% (27).
After the report of a link between cell proliferation and Eag1 expression, researchers
began to investigate links between cancer and Eag1 expression. Eag1 ectopic expres-
sion was observed in many cancer cell lines, including SHSY-5Y (28), IGR1 and IPC298
(29), EFM-19, MCF-7, and HeLa (21). Moreover, Eag1 protein has been detected in
3
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a wide range of human cancers, including soft tissue sarcomas (30) and cervical can-
cer (31). Furthermore, Eag1 was found in over 70% of all cancerous tissues screened
(32), while the corresponding healthy tissue was consistently free of Eag1 expression,
indicating an important link between Eag1 expression and cancer. Perhaps most in-
triguing, more aggressive soft tissue sarcomas were shown to express more Eag1 than
less aggressive soft tissue sarcomas (30). This relationship between Eag1 expression
and patient outcome suggests a direct link between Eag1 and poor prognosis.
Eag1-expressing tumors in SCID mice are also larger and more aggressive than
tumors that do not express Eag1 (21). We recently reported that Eag1-expressing
tumors are reduced in size by treatment with astemizole, a reduction similar to that
observed with cyclophosphamide treatment, a well established cytotoxic agent (33).
Interestingly Eag2, a 70% identical homolog of Eag1 (4), shows no relationship to
either cell proliferation or cancer. Eag2 shares many features with Eag1, including
both the Mg2+-, voltage-dependent Cole-Moore shift and a similar I-V relationship
(34) (though it opens at more negative voltages (35)). Moreover, it’s expression is
also largely restricted to the CNS (5) and is a candidate for the formation of heterote-
trameric Eag proteins. The absence of tumorigenic potential in Eag2 suggests that the
contribution of Eag1 to oncogenesis is only partly dependent on its canonical role as an
ion conductor, and may be more dependent on the large intracellular domains where
the least homology between Eag1 and Eag2 lie.
1.2 Hypoxia and Cancer
1.2.1 HIF Expression
Hypoxia exposure immediately leads to expression of the transcription factor Hypoxia
Inducible Factor-1 (HIF-1). The HIF transcription factor family is composed of 3
isoforms, HIF-1, HIF-2, and HIF-3, of which HIF-1 is the best studied and described.
HIF-1 is composed of a constituitively expressed β subunit and an α subunit which
is tightly regulated by prolyl hydroxylases (PHDs) and von-Hippel Lindau protein
(pVHL). Under hypoxic conditions, HIF-1α is expressed and dimerizes with HIF-1β,
translocates to the nucleus, and promotes transcription of hypoxia-inducible genes.
HIF-1 induction by hypoxia occurs near instantaneously, with a peak HIF-1 expression
approximately 4 hours after onset (depending on the cell line) (36). HIF-1 starts to
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stabilize at approximately 5-6% atmospheric O2, with half maximal activation occurring
near 2% O2 (37). HIF can be chemically induced by desferrioxamine (DFO) (38), Co2+,
and dimethyloxaloylglycine (DMOG).
1.2.2 HIF targets
HIF-1 was originally identified as a promoter of erythopoetin (EPO) expression (39) by
binding to the ”hypoxia response element” (HRE) of EPO under hypoxia (40). Since
then, HIF-1 has been shown to target a wide variety of hypoxia related genes, including
those involved in cell proliferation, metabolism, survival, inflammation, erythropoesis
and vascularization (Figure 1.2). One of the most influential targets of HIF-1 is vascular
endothelial growth factor (VEGF), a growth factor critical to the formation of new
blood vessels.
1.2.3 PHD and HIF
The HIF prolyl hydroxylases (PHDs) are a conserved family of 2-oxoglutarate and iron-
dependent dioxygenases that are the key oxygen sensors of the HIF regulation system.
PHD function is dependent on ascorbate as a co-factor and is inhibited by DFO, Co2+
and DMOG. PHD2 is the primary cellular oxygen sensor for HIF-1 under normal oxygen
conditions (41) and recognizes a LXXLAP motif (42) at P402 and P564 of HIF-1α
(aka the oxygen-dependent degradation domain; ODD)(43). PHD hydroxylates HIF-
1α prolines (44; 45) using atmospheric oxygen, tagging it for identification by pVHL
(46) (Figure 1.3). Prolonged hypoxia drives expression of PHD3 via HIF-1, generating
an inhibitory feedback machanism (47) as PHD3 hydroxylates HIF-1. Moreover, the
O2 Km of PHD3 is substantially lower than that of PHD2 (48), allowing it to function
in lower oxygen concentrations.
PHD interactions are not restricted to HIF regulation alone, however. PHD3 in-
teracts with and stabilizes the activating transcription factor-4 (ATF-4), indicating a
dual role for the PHD3 protein (51). Additionally, PHD2 has recently been shown to
interact with and be stabilized by FKB38 (52; 53).
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Figure 1.2: A selection of HIF target genes - taken from (49)
Figure 1.3: Regulation of HIF-1 expression. - HIF-1α is recognized under normoxia
and hydroxylated by prolyl hydroxylases. Hydroxylated HIF-1α is recognized by pVHL and
ubiquitylated, then degraded by the proteasome. Under hypoxic conditions, hydroxylation
is inhibited and HIF-1α escapes degradation and promotes transcription of hypoxia-relevant
genes. Taken from (50)
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1.2.4 pVHL and HIF
Von-Hippel Lindau disease is a rare autosomal genetic disease characterized by the
spontaneous formation of hemangioblastomas in the cerebellum, spinal cord, and retina.
First described by Eugen von Hippel in 1904 (54), VHL disease is caused by a mutation
in the vhl gene, commonly on or near Y98. These mutants cause the VHL disease by
inhibiting the ability of pVHL to recognize HIF. pVHL is a subunit of the E3 ubiquitin
ligase VHL complex (55) which includes Elongins B and C, Cul2, and Rbx1. pVHL
ubiquitylates hydroxylated HIF, targetting it for the proteasome and proteolysis (56).
Y98 is a critical residue for HIF recognition (57; 58) and mutation of the residue blocks
HIF ubiquitlyation. R167 is an important residue for binding to Elongins B and C and
expression of the R167W mutant prevents HIF-1 ubiquitylation by the mutant.
VHL has been proposed to have additional functions as well. pVHL has been
proposed to promote inhibitory phosphorylation of the NF-κB agonist Card9 by direct
binding (59), acting outside its putative role as a member of an E3 ligase complex.
VHL activity has also been proposed as relevant during neuronal differentiation (60),
independent of its role in regulating HIF-1 activity.
1.2.5 Tumors and hypoxia
Tumors are hypoxic environments. As they grow, new cells are added to the periphery
of the tumor while those in the tumor core become increasingly deprived of oxygen,
glucose, and other nutrients. Eventually, this starvation leads to hypoxia-induced apop-
tosis and necrosis (61). In order to increase in volume beyond a few mm3, tumors must
form new blood vessels to oxygenate their cells (For review, see (62)). This cellular
switch to turn on angiogenesis is highly dependent on oxygen concentration and occurs
via a HIF-1 dependent signal transduction process involving VEGF.
1.2.6 Ubiquitin
Ubiquitin is a small, 8kDa protein that is conjugated onto lysine residues of other
proteins. First characterized as a signal for protein degradation, a broad spectrum of
alternate conjugations has lead to a greater understanding of ubiquitin more generally
as a trafficking signal. Increasingly, other ubiquitin-like proteins (UBL) such as SUMO
(63) and Nedd8 (64; 65) are being identified as alternative signaling mechanisms for
7
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trafficking and protein function. Ubiquitin and other UBL signalling has also been
demonstrated to be important for ion channel trafficking and expression (for review,
see (66; 67)).
1.2.7 Eag1 and VHL
In 2002, a team of researchers researching the role of VHL on differentiation re-
ported that VHL expression caused differentiation of SHSY-5Y neuroblastoma cells
into neuron-like cells. In order to further demonstrate differentiation, they measured
Eag1 current density and noted a reduction of Eag1 in stably-transfected VHL cells.
Moreover, an increase in Eag1 current was observed in stable clones that showed in-
hibition of VHL expression (68). These data were not analyzed further, but rather
presented simply as demonstration of various stages of VHL-induced differentiation.
We interpreted this report as evidence of a possible cross-talk between Eag1 and the
HIF regulatory pathway. We also had previously observed a LXXLAP motif just outside
the PAS domain in the N-terminus of Eag1. We consequently began investigating
whether Eag1 physically and functionally interacts with PHD, VHL, or the proteasome,
and what the ramifications of any such interaction would be.
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Aims of the project
2.1 Project Scope
This project had two concurrent primary objectives. First, to identify whether the Eag1
ion channel is functionally modified by components of the HIF-1 cellular degradation
system, and the results of any such modifications on Eag1 activity. Second, to determine
whether ectopic expression of Eag1 altered the function of the HIF system such that
HIF activity and it’s downstream effects were altered.
2.2 Goals
1. To determine whether Eag1 is directly modified by any member of the PHD family
2. To determine whether VHL functions as an E3 ubiquitin ligase for Eag1.
3. To determine whether any of these candidate interactions affects proteasomal
degradation of Eag1.
4. To determine whether Eag1 expression alters expression of HIF and VEGF se-
cretion.
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3.1 Physical interaction with the HIF pathway
3.1.1 Eag1 and hypoxia
Because of the reported link between VHL expression and Eag1 current density as well
as the LXXLAP motif in Eag1 (see 1.2.7), I first studied the effects of chronic hypoxia
on steady-state Eag1 expression levels. Both SHSY-5Y (a natively Eag1 expressing
neuroblastoma cell line) and stably transfected HEK293 (Clone A) cells were exposed
to either 1% pO2 (hypoxia) or 21% (atmospheric) pO2 (normoxia) for up to 24h. Cells
were then recorded from using whole-cell patch clamp and current amplitude normalized
to cell surface as determined electronically by the patch clamp amplifier. Resulting
current density (pA/pF) from independent cells were processed (see 6.3, aggregated,
and statistically compared. No significant differences were detected in current density
in either cell line (Figure 3.1).
However, prolonged hypoxia induces a profound alteration in many cellular prop-
erties, including cell metabolism and protein synthesis. To limit the impact of any of
these effects, I measured the effect of hypoxia on hEag1 current density after inhibition
of de novo protein synthesis by cycloheximide. Using the method described above, cells
were treated with cycloheximide alone (10 µg/mL) or in conjunction with the prolyl
hydroxylase inhibitors 1% O2 (hypoxia), CoCl2 (400 µM) or DMOG (1mM). The pro-
lyl hydroxylase co-factor ascorbate (2mM) was used to observe the effects of enhancing
prolyl hydroxylase activity. Cycloheximide-alone treated cells showed a 50% decrease
11
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Figure 3.1: Eag current density under hypoxia - Neither SHSY-5Y (left) nor HEK293
Clone A (right) show changes in Eag1 current after 24 hr incubation under hypoxia.
of whole cell current density (3.2) after 8 hours, while 8 hours of hypoxia rescued this
effect, indicating a role for O2 in Eag1 surface expression.
Pharmacological mimicking of hypoxia with CoCl2 or DMOG also protected against
the decrease in current amplitude induced by cycloheximide. In contrast, pharmaco-
logical mimicking of hyperoxia by ascorbate exacerbated the current reduction by a
further 50%, to a value approximately 25% of the normal current density in the ab-
sence of cycloheximide (Figure 3.3).
Figure 3.4: Eag1 expression does not in-
duce redox changes - Eag1 expressing cells
(white) and HEK-PT cells (black) redox poten-
tial was compared. No difference in cellular re-
dox potential was observed.
It is possible that these hypoxia-
induced effects are side effects of
changes in cellular redox potential due
to changes in membrane voltage or in-
teraction with intracellular segments of
the channel. To verify that there is no
difference in cellular redox potential in
Eag1 expressing cells, cells were incu-
bated in the presence of Alamar Blue
(Biosource), a dye that is sensitive to
cellular oxidation state. The active in-
gredient in Alamar Blue is resazurin, a
non-fluorescent dye that is converted to
red-fluorescent resorufin via reduction
reactions of metabolically active cells
12
3.1 Physical interaction with the HIF pathway
Figure 3.2: Eag1 current reduction due to cycloheximide - Eag1 suffers a reduction
of current density upon application of 8hrs cycloheximide. This current reduction is rescued
by incubating the cells in hypoxia.
Figure 3.3: Eag1 current density affected by mimickers of hypoxia - CoCl2
and DMOG both rescue current reduction induced by cycloheximide. Current reduction
induced by cycloheximide is enhanced by co-culturing with ascorbate.
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(69). The amount of fluorescence is proportional to the number of living cells. No
changes were observed between Clone A and HEK293 cells stably transfected with an
empty vector (HEKPT) (Figure 3.4).
Because the effects of hypoxia, DMOG (an inhibitor), and ascorbate (a co-factor)
all target the same group of prolyl-4-hydroxylases (PHD), we considered them to be a
likely candidate for the direct modulation of hEag1 activity.
3.1.2 Eag1 and PHD
In collaboration with Prof. Dr. Katschinski and Dr. Koeditz of the Physiology Depart-
ment of the University of Göttingen, we first investigated possible in vitro interactions
between Eag1 and PHD1, 2 or 3. Because Eag1 is a complex transmembrane protein,
purifying the complete protein alone was outside our capabilities. Instead, we chose
to investigate only those segments of the channel that would likely interact directly
with a water-soluble protein - the intracellular C- and N- termini. For this purpose,
we began with a yeast two hybrid screen, performed by Dr. Jens Köditz. Eag1 N-
or C- terminus conjugated to the Gal4 activation domain (AD) was co-expressed with
prolyl hydroxylases conjugated to the Gal4 binding domain(BD). HIF-1α-AD was also
used as a positive control. Cells were grown on histidine-deficient media in the pres-
ence of varying concentrations of 3-Amino-1,2,4-triazole (3AT) in order to titrate the
minimum level of HIS3 expression required for growth. No interaction between PHD2
and either the C- or the N- terminus of Eag1 (Figure 3.5), while the HIF-1α ODD
(oxygen-dependent degradation domain) was observed to interact with PHD2.
Figure 3.5: Yeast 2-Hybrid screen between Eag1 and PHD2 - Neither N-terminus
nor C-terminus of Eag1 interacts with PHD2 (lanes 2, 3). HIF-1α ODD interacts with
PHD2 (lane 1). (Figure provided by Drs. Koeditz and Katchinski)
Both PHD1 and PHD3 interacted with the C-terminus of Eag1, suggesting a strong
interaction (Figure 3.6). No such interaction was observed the the N-terminus, sug-
gesting that any interaction could not be mediated by the N-terminus alone.
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Figure 3.6: Yeast 2-Hybrid screen between Eag1 and PHD3 - PHD3 interacts
with the C-terminus of Eag1 (bottom), but not the N-terminus. HIF-1α strongly interacts
with PHD3 as positive control. (Figure provided by Drs. Koeditz and Katchinski)
Figure 3.7: Yeast 2-Hybrid screen between Eag1 and PHD1 - PHD1 interacts
with the C-terminus of Eag1 (bottom), but not the N-terminus. HIF-1α strongly interacts
with PHD1 as positive control. (Figure provided by Drs. Koeditz and Katchinski)
To further verify the observed interaction with PHDs, we next investigated whether
a physical interaction occurred in vivo. Nitrocellulous membranes containing elec-
trophoresed HEK293 Clone A cell extracts were first probed via western blot for ex-
pression of each of the prolyl hydroxylases using a PHD antibody sample pack (Novus
Biologicals). Clone A cells were found to endogenously express both the constituitively
expressed PHD2 and the hypoxia-induced PHD3 (Figure 3.8).
Lysate from Clone A cells was then precipitated using either monoclonal antibodies
directed at the pore and C-terminus of Eag1 or an antibody against PHD2. Precipitated
protein was then electrophoresed, transferred to nitrocellulous membranes and probed
for either PHD2 (former) or Eag1 (latter). PHD2 was found to co-precipitate with Eag1
(Figure 3.9, left), albeit to a lesser extent than Eag1 with itself. Mock-transfected cells
showed no reaction, indicating that the antibody used for the detection was specific
for Eag1 (data not shown). In contrast, Eag1 was found to co-precipitate with PHD2
(Figure 3.9, right). In this case, some non-specificity in the monoclonal antibodies used
to precipitate the extract was observed, as a band was detected where absent in extract
precipitated in the absence of antibodies.
Together, these data suggest that the functional regulation of Eag1 surface expres-
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Figure 3.8: HEK293 Clone A expression of PHDs - Clone A extracts show robust
expression of both PHD2 and the HIF-induced PHD3. PHDs 1 and 4 do not show strong
expression in Eag1-expressing HEK cells. (Figure provided by Dr. Sánchez )
Figure 3.9: Immunoprecipitation of Eag1 with PHD2 - HEK293 Eag1 Clone A cell
extracts precipitated with an anti-PHD2 monoclonal antibody can be detected with an
anti-Eag1 antibody, while extracts precipitated with an anti-Eag1 antibody show robust
detection (left panel). Conversely, extracts precipitated with an anti-Eag1 antibody show
a strong PHD2 specific band using an anti-PHD2 antibody (right panel, left). While non-
specific precipitation occurs in extracts prepared from mock-transfected cells (Mock), no
precipitation of PHD2 is observed with beads alone. (Figure provided by Dr. Sánchez )
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sion by PHD. This effect may be a direct modification (e.g. hydroxylation) of Eag1 or
that of an Eag1 binding partner. However if there is a direct hydroxylation of Eag1 by
PHD, it may lead to further interactions between Eag1 and other elements of the HIF
regulation system, such as VHL, ubiquitin, and the proteasome.
3.1.3 Eag1 and VHL
While other groups have already observed a functional correlation between VHL ex-
pression and Eag1 current (68), we wanted to know whether there was a direct inter-
action between pVHL and Eag1. Using an in vitro GST-pulldown assay, we examined
whether there existed a PHD dependent or independent interaction between Eag1 and
VHL. GST-tagged Eag1 N- or C- terminus protein was expressed in E. Coli, puri-
fied, and immobilized on a glutathione affinity gel. The gel was then treated with a
VHL-elonginB-elonginC (VBC) complex and probed for VBC expression.
While either PHD2 or PHD3 were necessary for a VHL interaction with the HIF-2α
ODD, no interaction was observed between VHL and the N-terminus of Eag1 (Figure
3.10). However, the C-terminus of Eag1 was observed to interact with VHL in a PHD
independent way, with no increase of VHL pulled down with the addition of PHD2 or
PHD3 (Figure 3.11).
Figure 3.10: GST pulldown of VHL and Eag1 N-terminal - The N-terminal of Eag1
shows no interaction with VHL, either without PHD (column 7), with PHD2 (column 8),
or with PHD3 (column 9). HIF-2α ODD pulls down VHL only in the presence of PHD2
(column 5) or PHD3 (column 6). (Figure provided by Drs. Koeditz and Katchinski)
To verify that this interaction could occur in vivo, we repeated the immunoprecip-
itation assays above for VHL and Eag1. Clone A cells were chosen for consistency,
while SHSY-5Y cells were probed due to the already established functional relationship
17
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Figure 3.11: GST pulldown of VHL and Eag1 C-terminal - The C-terminal of
Eag1 interacts with VHL both with PHD2 and PHD3 (columns 8 and 9) and without
PHD (column 7). HIF-2α ODD pulls down VHL only in the presence of PHD2 (column
5) or PHD3 (column 6). (Figure provided by Drs. Koeditz and Katchinski)
Figure 3.12: Immunoprecipitation of Eag1 with VHL in HEK293 and SHSY-5Y
- (left panel) Clone A extracts precipitated with anti-VHL antibody were detected with
antibodies against Eag1 (middle lane). No signal was detected in extracts precipitated from
mock-transfected cells (right lane) and a faint signal was observed in Clone A extracts
precipitated without antibody (left lane). (right panel) SHSY-5Y extracts precipitated
with anti-VHL antibody were detected with antibodies against Eag1 (right lane). No signal
was observed in SHSY-5Y extracts treated without antibody (left lane).(Figure provided
by Dr. Sánchez )
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between natively expressed Eag1 and VHL in these cells. Using an anti-VHL antibody,
Clone A extracts showed strong co-precipitation, while SHSY-5Y cells showed faint, but
observable, co-precipitation (Figure 3.12). Because the size of VHL is approximately
the same as the light chain of the antibody, no Eag1 precipitation and VHL detection
was performed. Together, these blots indicate that Eag1 physically interacts with VHL
in both heterologous and native systems and supports the interpretation that Eag1 is
directly modified by VHL.
3.1.4 Eag1 and ubiquitylation
VHL is a well described tumor suppressor that functions as an E3 ubiquitin ligase. It is
the only E3 that has been described to recognize the HIF family, and its interaction with
Eag1 could lead to ubiquitylation of the ion channel. In order to investigate this, we first
wanted to determine whether Eag1 was ubiquitylated in vivo. Cell extracts of Clone
A cells treated with MG115 (a potent proteasomal inhibitor, used to enrich ubiquity-
lated proteins) for 4 hours showed considerable Eag1 specific signal after anti-ubiquitin
precipitation (Figure 3.13). No such signal was observed in either mock treated cells
or cell extracts precipitated without antibody. This co-immunoprecipitation suggests
that Eag1 is ubiquitylated in heterologous systems.
Figure 3.13: Immunoprecipitation of Eag1 with Ub in HEK293 - (Clone A extracts
precipitated with anti-Ub antibody were detected with antibodies against Eag1 (middle
lane). No signal was detected in extracts precipitated either from mock-transfected cells
(right lane) and without antibody (left lane)).(Figure provided by Dr. Sánchez )
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3.2 Functional interaction with the HIF pathway
3.2.1 Effect of PHD and VHL knockdown on Eag1
Because of the observed interactions between Eag1 and VHL/PHD and because of the
co-immunoprecipitation of Eag1 and ubiqutin, I next asked whether Eag1 ubiquityla-
tion was PHD or VHL dependent. Clone A cells were transfected with siRNA targeted
against PHD2, PHD3, Eag1, or with a non-coding sequence of siRNA purchased from
Ambion (Scrambled). Cells were harvested 2 days after transfection, lysed, and im-
munoblotted for Eag1 expression. Compared to non-targetted siRNA, knockdown of
PHD2 seems to reduce the Eag1-specific high molecular weight signal (Figure 3.14),
a finding compatible with PHD-mediated ubiquitylation of Eag1. Important to note,
however, is that scrambled siRNA seems to evoke a stabilization of high molecular
weight Eag1, most likely due to a siRNA-mediated stress response.
Figure 3.14: Eag1 interaction with PHD - Extracts from siRNA transfected Clone
A cells were probed for Eag1 expression. Knockdown of PHD2 decreases the amount of
high molecular weight Eag1 (top) as compared to Scrambled, while PHD3 knockdown has
a lesser role. No effect of anti-PHD siRNA on the normal 100kDa Eag1 double band is
observed (middle). Anti-Eag1 siRNA shows an as-expected reduction of Eag1 protein.
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I next investigated whether this effect on high molecular weight Eag1 upon inhi-
bition of PHD was due to ubiquitylation of Eag1. HEK-Eag1 cells were either trans-
fected with siRNA against PHD or VHL or treated with inhibitors of PHD (hypoxia
and DMOG). Untransfected cells were treated for 4 hours with 1% O2 or 1mM DMOG,
and all cells were treated during this incubation with 10µM MG115 to enrich Eag1-
ubiquitin immunoprecipitation. Scrambled siRNA was used as a negative control for
siRNA treatment. Eag1 protein was precipitated and detected as above (Figure 3.15).
While MG115 treatment alone enriches Eag1-Ub immunoprecipitation (and to a
lesser extent enriches Eag1 precipitation), both hypoxia and DMOG treatment cause
an overall reduction of Eag1-Ub immunoprecipitation. This hypoxia/DMOG reduc-
tion occurs both in the presence and absence of MG115 (data not shown). Moreover,
treatment with anti-PHD2, anti-PHD3, and anti-VHL siRNA all slightly reduce Eag1-
ubiquitin immunoprecipitation. It is also noteworthy that MG115 treatment alone does
not enrich detection of the 100kDa Eag1 double band after immunoprecipitation with
anti-Eag1 antibodies. These data indicate that Eag1-ubiquitin immunoprecipitation is
at least partly dependent on PHD activity, as inhibition of PHD dramatically reduces
Eag1-ubiquitin co-immunoprecipitation.
Figure 3.15: Eag1-Ubiquitin immunoprecipitation is affected by PHD and VHL
knockdown - HEK cells treated with anti-PHD2, anti-PHD3, or anti-VHL siRNA show re-
duced Eag1-Ub immunoprecipitation as compared to treatment with non-targetted siRNA
(scrambled, top). Treatment with either 1% O2 or 1µM evokes a stronger reduction of
Eag1-ubiquitin immunoprecipitation. All lanes show similar precipitation of Eag1 protein,
with the possible exception of hypoxia and DMOG treated cells (middle). Actin probes of
10% load show equivalent protein load in each lane (bottom)
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3.2.2 Effect of PHD and VHL transfection on Eag1
Figure 3.16: Eag1 interaction with PHD
and VHL - Cell extracts were precipitated
using a combination of monoclonal mouse an-
tibodies against Eag1 and detected with ei-
ther an anti-ubiquitin antibody (top) or a poly-
clonal Eag1 antibody (bottom). More Eag1
precipitated with ubiqutin in VHL WT trans-
fected cells as mock transfected cells (pcDNA).
Further interpretation is made difficult due to
differences in Eag1 precipitation, but PHD2
and PHD3 both appear to affect Eag1 co-
precipitation with ubiquitin, while VHL mu-
tants reduce Eag1 co-precipitation with ubiq-
uitin.
Clone A cells were also transfected with
PHD, VHL, or the empty vector to de-
termine whether over-expressing PHD
or VHL would affect Eag1-ubiquitin co-
immunoprecipitation. Clone A cells
were transfected with either PHD2 or
PHD3, as well as a functional mutant of
PHD3 (H196A) which does not hydrox-
ylate HIF. Additionally, VHL wild type
and VHL mutants Y98H (a dominant
negative mutant that does not bind
HIF) and R167W (an inactive mutant
that is not dominant negative) were
also transfected. Cells were transfected
with coding DNA or the empty vec-
tor (pcDNA) and incubated for 2 days,
then treated with MG115 for 4hrs and
harvested. Whole cell extracts were
immunoprecipitated with a mixture of
monoclonal mouse antibodies directed
against the pore and C-terminus of
Eag1, and detected with anti-ubiquitin antibody. Only cells transfected with VHL
WT show an enrichment of a 100kDa Eag1 band, while no change was observed in high
molecular weight Eag1 (Figure 3.16.
The reverse of this experiment was also performed, precipitating extract with anti-
ubiquitin bound beads and detecting using a polyclonal rabbit antibody against Eag1,
but extensive non-specific detection made interpretation of the data extremely difficult
(data not shown).
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3.2.3 In vitro ubiquitylation assay of Eag1 c-terminus
To further verify whether ubiquitylation is VHL-mediated, an in vitro VHL ubiquityla-
tion assay was performed. Rabbit reticulocyte lysate was mixed either with HIS-tagged
Eag1 C-terminus cDNA or without (no DNA). The translated protein was then incu-
bated either without further addition, or with a cocktail containing E1, Ubc3, Ubc5
(both E2 ligases important for the degradation of HIF-1α), VHL, and ubiquitin. Im-
mediately after addition of this second cocktail, the translated protein was either im-
mediately denatured and frozen (”0 min”) or incubated for an additional 90 minutes
(”90 min”). This protein cocktail was then electrophoresed through a 5-15% gel, trans-
ferred, and detected using either an anti-Eag1 polyclonal c-terminus antibody (9391)
or an anti-HIS antibody (Figure 3.17).
Figure 3.17: in vitro ubiqutylation of Eag1 c-terminus. - Rabbit reticulocyte lysate
was treated for 0 or 90 minutes (”0 min”, ”90 min”, respectively) with or without VHL
(”-VHL”, ”+VHL”, respectively). Lysate was also pretreated either with Eag1 c-terminus
cDNA or without (”no DNA”). Lysate was then detected using anti-HIS antibody (top)
or using an anti-Eag1 c-terminus antibody (bottom).
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A 75kDa band was observed using both the 9391 and the anti-HIS antibody, an
observation that was consistently reflected as this experiment was repeated. Eag1
and HIS detection both suggest that this band is not-specific to Eag1, as the band
exists in lanes in which no Eag1 cDNA was added. Most importantly, while a high
molecular weight smear was detected above 130kDa in VHL treated lysate using the
9391 antibody, this signal was not noticeably stronger than that found in lysate not
treated with VHL. Furthermore, no high molecular weight signal could be detected
using the anti-HIS antibody. If anything conclusions can be made from these results,
it is that VHL is not necessary in this system for the ubiquitylation of Eag1. However,
it does not preclude the possibility that an E2 other than Ubc3 or Ubc5 is important
for VHL-mediated ubiquitylation.
3.3 Possible Eag1 degradation pathways
3.3.1 Eag1 and the proteosome
Figure 3.18: S35 labelled Eag1 degrada-
tion - A faint double band can be observed in
Eag1 expressing cells that is not present in non-
Eag1 expressing cells. MG115 treatment causes
an increase in band intensity as compared to
untreated, while DMOG treated cells show an
elimination of the Eag1-specific band.
Ubiqutylation is usually, but not al-
ways, a signal to target a protein for
proteasome-mediated degradation. To
investigate this, I instructed a stu-
dent in patch clamp electrophysiology
who compared Eag1 whole cell cur-
rent density in Clone A cells treated
with MG115 and cycloheximide. Cells
treated with MG115 for 8 hours showed
a similar rescue of cycloheximide-
induced current density as treatment
with hypoxia or DMOG (Figure 3.19,
left panel). Immunoblot experiments
on whole cell extract show a great in-
crease in Eag1 protein after only 4 hours, compatible with the rapid degradation nor-
mally associated with ubiquitin-mediated degradation.
A possible interpretation for this MG115/cycloheximide effect could be changes in
channel permeability. In order to conclusively determine whether the MG115-mediated
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Figure 3.19: Eag1 interaction with the proteasome - (left panel) MG115 (10µM)
and cycloheximide(10µg/mL) treated cells show an enrichment of whole cell current density
as measured by patch clamp electrophysiology (right panel). Clone A whole cell extract
show an enrichment of Eag1 signal after 4hrs treatment with MG115 (10µM). No signal
is detected in mock transfected cells with or without MG115. (Left panel provided by Ye
Chen; right panel provided by Dr. Sánchez )
enrichment of Eag1 protein and current density is due to alterations in protein degrada-
tion, S35 pulse chase experiments were performed on Clone A cells. Cells were starved
of cysteine and methionine for 30 minutes, then supplied with S35 labelled cysteine
and methionine for 30 minutes. Cells were subsequently either immediately lysed, or
incubated without labelled amino acids for 4 hours in the presence of MG115 or DMOG
(Figure 3.18). A faint double band can be observed in HEK-Eag1 cells that is difficult
to recognize in HEK-PT cells. Moreover, this double band intensifies upon treatment
with MG115, while DMOG treatment reduces the intensity of the Eag1 signal. These
results suggest that DMOG treatment enhances Eag1 degradation, rather than inhibits
it, a finding at odds with previous results. However, the intensification of an Eag1 sig-
nal upon treatment with MG115 is in good agreement with both the electrophysiology
and western blot data.
3.3.2 Eag1 and the lysosome
Hydrophobic proteins are often degraded in the lysosome, and given the large trans-
membrane segments of Eag1, I also wanted to see whether blocking the lysosome had
any effect on Eag1 expression. Clone A cells were transfected with V5-tagged BACE, a
lysosomally degraded protein in neurons. As BACE degradation is blocked upon treat-
ment with the lysosomal blocker chloroquine (CQN), detection of V5-BACE enrichment
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was used as a positive control. Transfected cells were treated 2 days later with either
MG115 or CQN. In both cells transfected and untransfected with BACE, 24 hrs of
200µM CQN treatment induced an enrichment of Eag1 protein, particularly strength-
ening an 80kDa band (Figure 3.20). This effect was also observed in cells transfected
with BACE and treated with 10µM MG115 for 4hrs, suggesting that BACE expression
in some way helps stabilize this product, possibly by interaction with the lysosome.
While it is possible that the MG115 induced expression of BACE-mediated stabi-
lization of the 80kDa band is artifactual in nature, the CQN enrichment of this band
was reproducible and seems to indicate a role for the lysosome in Eag1 expression.
Figure 3.20: Eag1 interaction with the lysosome - Chloroquine (200µM, 24hrs)
treated cells show an increase in an 80kDa band which is not observed in untreated cells.
This band also appears in MG115 treated cells (10µM, 4hrs), although only in those cells
transfected with V5-BACE. CQN treated cells show an enrichment in V5-BACE over un-
treated cells.
3.4 Eag1 induction of HIF and it’s consequences
3.4.1 Eag1 expression stabilizes HIF-1
If Eag1 functionally interacts with components of the HIF-1 degradation pathway,
it could affect HIF-1 expression. To investigate this, HIF-1 expression in HEK293
Eag1 Clone A and mock transfected cells were compared after 4hrs of normoxic (21%
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O2) or hypoxic (1% O2) conditions. Initially, this experiment was performed using
western blots, but difficulties in finding reliable and clear differences between Eag1
expressing cells and mock-transfected cells led me to examine the expression of HIF
using flow cytometry. After treatment, cells were fixed with 4% paraformaldehyde and
permeabilized with 0.6% saponin. Permeabilized cells were then treated with an anti-
HIF-1 monoclonal antibody and probed with a Cy5 conjugated secondary antibody.
Figure 3.21: HIF-1 changes in Clone A
using flow cytometry. - Eag1 expressing cells
under normoxia (21% pO2; blue) show an in-
crease in HIF expression as compared to mock-
transfected cells under normoxia (red). Both
mock and Eag1 expressing cells under hypoxia
(1% pO2 show more HIF expression under hy-
poxia, although Eag1 expressing cells (orange)
still show an increase over mock (green).
Because of the sensitivity of the
flow cytometry instrument, differences
in expression can be quantified and
statistically compared. Initial experi-
ments demonstrated that Eag1 express-
ing cells exhibited an increase in HIF-
1 under both hypoxic and normoxic
conditions (Figure 3.21). However, as
Clone A is a monoclonal cell line, in-
creases in HIF stability could be due
to clonal insertion into the DNA and
not due Eag1 expression. To miti-
gate this possibility, HIF expression in
two additional monoclonal cell lines ex-
pressing Eag1 (selected for robustness
of Eag1 current as measured via whole
cell patch clamp) were compared. All
three cell lines were seen to exhibit an
increase of 50% in HIF-specific fluores-
cence over mock-transfected cells (Fig-
ure 3.22).
A more relevant assay of HIF ex-
pression is to actually measure its activity. After transfecting Clone A or mock-
transfected cells with a luciferase vector driven by the HIF-spectific HRE (hypoxia
response element) promoter region, cells were either left untreated or exposed to mock-
hypoxia by treatment with 200 µM CoCl2 for 4 hours. Cells were then lysed and
evaluated for luciferase expression using a high-sensitivity luciferase activity assay kit
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Figure 3.22: HIF-1 changes in three monoclonal Eag1 cell lines. - Three Eag1
expressing cells under normoxia show increases in HIF expression as compared to mock-
transfected cells.
(Roche). Under both normoxia and mock-hypoxia conditions, Eag1 expressing cells
showed an elevation over mock-transfected cells (Figure 3.23). It is important to note
that both mock and Eag1 expressing cells react positively to the presence of chemically
induced hypoxia, as indicated by the change in scale between the two graphs. This
result shows that the HRE vector responds to HIF activity.
Figure 3.23: HRE response in Eag1 expressing cells. - Eag1 expressing cells show
increases in HRE activity under both 21%O2 (left panel) and 200 µM CoCl2 (right panel).
An interesting question is whether the change in HIF expression correlates to a
change in oxygen sensitivity - i.e. whether Eag1 expressing cells begin expressing
HIF at a higher oxygen concentration than non-Eag1 expressing cells. This can be
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determined by titrating both cell lines with CoCl2, replicating varying atmospheric
oxygen concentrations while preventing errors due to changes in transfection efficiency
or incubators. After normalizing data to HIF activity in the absence of CoCl2, Eag1
expressing cells were observed to show a greater sensitivity to CoCl2 treatment, inducing
HIF with as little as 50uM CoCl2, while mock and untransfected cells both showed no
induction of HIF at that concentration (Figure 3.24).
Figure 3.24: Changes in HRE induction in Eag1-expressing cells. - Eag1 express-
ing cells (black circle) show earlier induction of HRE activity after treatment with CoCl2
than mock (white square) or untransfected cells (white circle). Data was normalized for
each cell line to its own HRE activity in the absence of CoCl2 (0 µM).
Because Clone A cells show a greater sensitivity of the HIF system, we expected to
find a more dramatic change in HIF expression under mild hypoxia. Clone A or mock
transfected cells were treated to 5% O2 for 4 hours and lysed using a 8M urea containing
buffer to immediately stop all cellular activity, as HIF degradation upon reoxygenation
occurs on an order of minutes. Cell extracts were analyzed using western blot and Clone
A cells demonstrated a clear increase in HIF expression over mock-transfected cells
(Figure 3.25), while under 7% O2, Eag1 expressing cells showed clear HIF expression
while mock-transfected cells did not (data not shown).
If there is a direct correlation between Eag1 expression and HIF-1 (for example,
stabilization of HIF via competitive binding to the enzymes that regulate HIF degra-
dation), then targetting Eag1 for knockdown in stably transfected cells should reduce
HIF expression in these cells. To examine this possibility, cells were transfected with
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Figure 3.25: HIF expression under mild hypoixa. - Clone A extracts treated
with mild hypoxia (5% O2) showed an increase in HIF expression over mock transfected
cells.(Figure provided by Dr. Sánchez )
anti-Eag1 siRNA and probed for HIF expression. Cells were left to incubate for up to 3
days, subjected to 5% O2 for 4 hours, and lysed. While knocking down Eag1 produced
an increase in HIF expression, this did not appear to be a specific effect, as undirected
siRNA (Ambion) produced a similar response 2 days after incubation (Figure 3.26).
To further investigate whether this HIF stabilization could be due to an off-target
effect of the siRNA, Clone A cells were co-transfected as described earlier with the HRE
luciferase vector used previously (3.20) and one of four untargetted siRNAs, including
the Ambion negative control used above (Scrambled 1). These values were compared
to cells transfected with no siRNA, both with and without treatment of 100µM DMOG
for 22 hours (a mild mimicker of hypoxia). Only one scrambled siRNA (#3) showed a
response equivalent to cells transfected without siRNA (Figure 3.27). Troublingly, one
of the scrambleds (#4) evoked an HRE response stronger than mock-hypoxia treated
cells.
3.4.2 Eag1 and VEGF
Among the many factors influencing angiogenesis, vascular endothelial growth factor
(VEGF) appears to be predominant. VEGF has drawn intense attention in the field of
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Figure 3.26: Eag1 knockdown influence on HIF-1 expression. - Clone A extracts
treated with mild hypoxia (5% O2, 4hrs) 1, 2, or 3 days after transfection with anti-Eag1
show an increase in HIF expression over untreated cells. A similar result is observed in
cells transfected with non-targetting siRNA.
Figure 3.27: Effect of non-targetted siRNA on HIF response. - Clone A extracts
were co-transfected with one of four non-targetting siRNA complexes. Three of four show a
change in expression of the HRE luciferase reporter vector as compared to cells transfected
only with the HRE luciferase reporter vector. As positive control, cells transfected only
with the HRE reporter vector were treated with 100 µM DMOG.
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oncology due both to its influence on tumor survival and to its potential use in cancer
therapies. Because a direct consequence of HIF-1 activation is almost always increased
VEGF secretion, I determined VEGF abundance in the culture supernatant of cells
expressing Eag1.
Figure 3.28: VEGF secretion from Eag1 cells - Clones A, B, and C all show more
VEGF secretion as measured by ELISA than mock-transfected cells.
Cell culture media for each cell line was replaced and extracted 22 hours later.
VEGF secretion was measured and normalized to cell total protein content in three
independent clones of the HEK293 cell line stably expressing Eag1 by ELISA (Clones
A, B, and C) and compared to mock-transfected cells. All three Eag1 expressing cell
lines were found to secrete two to three times more VEGF than the non-transfected
control (Figure 3.28).
Because human Eag1 tumorigenic effects have been studied using mouse and hamster-
derived tumors, the effects of Eag1 on VEGF secretion was also studied in 3T3 and
CHO cells. Both cell lines show an increase in VEGF secretion as compared to wild-type
cells (Figure 3.29).
3.4.3 Tissue consequences of Eag1 expression
As VEGF is the predominant growth factor in promoting neo-angeogenesis in vivo, we
also examined vascularization in tumors derived from SCID mice. Tumor slices were
stained with CD31, a marker for endothelial structures, and thus blood vessels. Eag1
expressing tumors were found to contain distinctly more blood vessels as tumors derived
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Figure 3.29: Eag1-mediated VEGF secretion in non-human cells. - Both 3T3
and CHO cells secrete more VEGF when expressing Eag1.
from control cells (Figure 3.30). Quantification of blood vessel surface area found an
increase of 2.5 in total blood vessel surface area in Eag1-derived tumors as control
tumors (data not shown).
Figure 3.30: Vascular staining of Eag1 and control tumors - Tumors derived from
Eag1 cells implanted into SCID mice show more vascularization (right panel) than control






4.1 Eag1 and mTOR/MAPK
mTOR (mammmalian target of rapamycin) is a large signalling kinase complex that is
a key regulator of mRNA translation by regulating eIF4E phosphorylation. It has been
extensively studied, although many of the initial discoveries stem from its name, when
it was first discovered that the antifungal and immunosuppresent drug rapamycin in-
hibited mTOR activity. mTOR inhibition leads to a reduction in protein synthesis, and
can also be triggered by hypoxia, starvation of amino acids, and cellular stress. More-
over, a direct link between mTOR activity and HIF-1α expression has been observed,
most likely by translational regulation (for review, see (? )).
MAPK is an important kinase that responds to mitogen signals via PI3K and
regulates gene expression, proliferation, and cell survival. Recently, Eag1 expression
has been linked to MAPK activity, suggesting a different role for Eag1 in tumorigenesis
(70).
4.1.1 Eag1, HIF, and mTOR
As mTOR is an important regulator of ER-associated degradation and PI3K activity
has been increasingly shown to be regulated by ion channel activity (for example, see
(? ? )), we decided to first investigate any possible role mTOR inhibitors might have
on Eag1 and HIF activity. To begin, I investigated what the effect of mTOR inhibition
would be on HIF expression in mock-transfected cells and cells expressing Eag1. Whole
cell extract prepared from cells treated with 200nM rapamycin and mild hypoxia (7%
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O2) were immunoblotted with anti-HIF antibodies. While PT cells showed a decrease
in HIF expression after treatment with rapamycin, Eag1 expressing cells showed no
such reduction (Figure 4.1).
Figure 4.1: Eag1-induced alteration in HIF expression under rapamycin. -
While mock-tranfected cells (left) show a reduction of 7% O2-induced HIF stabilization
after treatment with 200nM rapamycin for 4 hrs, no such reduction is observed in Eag1
expressing cells (right). No similar discrepency is observed in cells further deprived of
serum.
Because VEGF secretion is tightly linked to HIF expression, cell culture super-
natant was probed for VEGF concentration using ELISA technology as described ear-
lier. Mock-transfected cells show an overall reduction in VEGF secretion when treated
with rapamycin for 4 hrs at 7% O2, an effect which is exacerbated when incubating
cells in the absence of serum (Figure 4.2). Conversly, Eag1 expressing cells show no
appreciable reduction in VEGF secretion upon treatment with rapamycin, regardless
of the presence of serum or not.
4.1.2 Eag1 expression and MAPK
To further investigate the role of mTOR in Eag1-expressing cells, we purchased a multi-
plex antibody cocktail which allows for the probing of multiple phosphorylated proteins
on a single membrane (Pathscan Multiplex Western Blot Cocktail I, Cell Signalling
Technologies). Cells were cultured with a combination of 7% O2, serum starvation,
and/or 200nM rapamycin. Cells were then lysed, electrophoresed, and transfered to a
nitrocellulous membrane for immunoblotting. Upon treatment with the Western Blot
Cocktail, two observations were clear: While mock-transfected cells without serum and
rapamycin, but with hypoxia, showed no increase in phosphorylated S6 (a marker of
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Figure 4.2: Eag1-induced alteration in VEGF secretion under rapamycin. -
While mock-tranfected cells (left) show a reduction of 7% O2-induced VEGF secretion
after treatment with 200nM rapamycin for 4hrs, no such reduction is observed in Eag1
expressing cells (right). Note that mock-transfected serum deprived cells do not reflect the
stabilization of HIF-1 observed in ??.
mTOR activity) (Figure 4.3; lane 6), Clone A cells showed strong phosphorylation of
S6 under similar conditions ((Figure 4.4; lane 6). Moreover, Clone A cells showed a
strong activation of MAPK in the presence of serum under all conditions, whereas PT
cells did not.
4.1.3 Conclusions
Interpretation of the finding that Eag1-expressing cells are not as sensitive to rapamycin-
induced HIF inactivation as mock-transfected cells is difficult in light of the finding that
Eag1 expressing cells show an overall increase in HIF expression. There are many pos-
sibilities: HIF or Eag1 expression could de-stabilize the mTOR pathway, reducing its
influence on protein translation. Eag1 could interact directly upstream of mTOR, per-
haps by an interaction with PI3K at the plasma membrane. Or perhaps alteration of
MAPK activity affects mTOR activity.
The finding that S6 activity is not inhibited under hypoxia by serum deprivation
suggests an overall robustness in the mTOR pathway, which may or may not be related
to MAPK activity. The finding that Eag1-expression induces p38-MAPK activity is
not novel, but the signal intensification upon serum deprivation seems a promising
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Figure 4.3: HEK PT activation of MAPK/mTOR - Mock-transfected cells exhibit
phosphorylated S6 without rapamycin under normoxia, but serum starvation blocks P-S6
under 7% O2 (lane 6 ). MAPK shows mild activation under all conditions tested.
Figure 4.4: Eag1 activation of MAPK/mTOR - Mock-transfected cells exhibit phos-
phorylated S6 without rapamycin under both normoxia and 7% O2. MAPK shows strong
activation in the presence of serum and mild activation for all other conditions.
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lead. This work is not complete and will require further investigation to determine any
Eag1-MAPK-mTOR link.
4.2 siRNA knockdown of Eag1 current density
As part of a technical paper on the effects of siRNA knockdown of Eag1 on proliferation,
I verified the effects of anti-Eag1 siRNA on current density (22). Cells were transfected
as described earlier with anti-Eag1 siRNA and whole-cell current density was measured
either 24h or 72h post-transfection. Anti-Eag1 siRNA treatment completely eliminated
Eag1 current density as compared to non-targetted siRNA 24h after transfection (Fig-
ure 4.5, left). This effect was completely recovered 72hrs after transfection (right).
Figure 4.5: Eag1knockdown by siRNA - HEK293 Eag1 clone A cells were transfected
with anti-Eag1 siRNA or non-targetting siRNA and Eag1 current density measured using
whole cell patch clamp either 24h (left) or 72hr (right) later. 24h after transfection, anti-
Eag1 siRNA produced a complete reduction of Eag1 current density, which was completely
recovered 72h post-transfection.
4.3 Chemical modification of HERG blockers to reduce
channel affinity
HERG blocking can induce LQTS, a cardiac disorder that can trigger arrhythmia and
lead to sudden death (71). Approximately 3% of all drug prescriptions involve med-
ications that cause LQTS (72). Due to the frequency and severity of this problem
regulatory agencies require that every new drug be assessed for its propensity to in-




HERG blockers act on the intracellular side of the channel by binding to specific
residues (74). Due to the unique molecular features of HERG, many drugs with diverse
chemical structures can block this channel (75). Such promiscuous and unpredictable
binding of compounds to HERG has frustrated attempts to design drugs that minimise
HERG blockage while maintaining activity for the therapeutic target (72). To address
this crucial issue, we made a common chemical modification to a HERG blocker that
prolongs the QT interval, the antihistamine astemizole (AST) (76). This modification
ensured that these drugs remained in the extracellular media.
4.3.1 NMA block of HERG
Astemizole (AST) is potent blocker of HERG that has an IC50 in the nano-molar
range. By chemically modifying the hydrophobic chemical via N-alkylation to perma-
nently add a positive charge, the new N-methyl-astemizole-iodide (NMA) should lose
any affinity for HERG as it would be unable to cross the plasma membrane and reach
its intracellular binding site. Stably transfected HEK293-HERG cells were recorded
from using whole-cell patch clamp and perfused with either AST or NMA. High con-
centrations of NMA (500nM) produced a HERG tail current reduction of only 15%,
while substantially lower concentrations (30nM) of AST produced tail current reduc-
tion of 70% (Figure 4.6). While AST was determined to be a high affinity blocker with
an IC50 of approximately 12nM, NMA was classified as a low-affinity blocker with an
IC50 of approximately 2µM (Figure 4.6, right).
Figure 4.6: HERG current in response to N-Methyl Astemizole - Left: HERG
currents in permanently transfected HEK-293 cells in response to a 1s depolarization to +40
mV from a holding potential of 70 mV, and subsequent return to holding voltage for 0.5 s.
The traces represent the steady-state blockage obtained with the indicated concentration
of the different blockers; C, Control; AST, Astemizole; NMA, N-Methyl Astemizole. The
dashed line indicates the zero current level. Right: Calculated HERG IC50 for AST and
NMA. AST exhibits IC50 of 12nM, while NMA has an IC50 of 2µM.
40
4.3 Chemical modification of HERG blockers to reduce channel affinity
4.3.2 Conclusion
N-alkylation is a simple and effective chemical modification to prevent hydrophobic
compounds from crossing the plasma membrane and reaching intracellular targets.
While this may not be desirable for compounds whose primary targets are intracellu-







Despite several studies implicating Eag1 ectopic expression in many cancer cell lines
and primary tumors (21; 22; 23; 29; 30; 31; 32), it is only recently that evidence for
the mechanism of Eag1s contribution to tumorigenesis has begun to come to light (33).
This work describes a candidate mechanism for the extraordinary rate of expression of
Eag1 in human tumors by stabilizing HIF expression and promoting VEGF secretion
and angiogenesis. It seems likely that this pro-oncogenic behavior is due to a direct
and functional interaction between Eag1 and the important elements of the HIF degra-
dation pathway; PHD, VHL, and the proteasome. Such an interaction could lead to
an inhibition of HIF binding to these regulators, causing a competitive inhibition of
HIF degradation. In effect, Eag1 binding to PHD and VHL stabilize HIF and promote
angiogenesis.
5.1 Eag1 physically and functionally interacts with prolyl
hydroxylases
Eag1 current density is strongly inhibited upon protein synthesis inhibition, an effect
that is counter-acted by incubation under hypoxia (3.2). This effect is not observed
in the absence of cycloheximide (3.1, and occurs in cells expressing the channel under
the control of a non-native promoter, strongly indicating a post-translational, oxygen
dependent modification of Eag1 or its interacting partners. This modification cannot
depend on HIF-1α, because the inhibition of protein synthesis by cycloheximide blocks
the activity of HIF-1α (77). Inhibition of prolyl-hydroxylase (by DMOG) mimics the
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effects of hypoxia, while its stimulation by ascorbate produces a further reduction of
current density under normoxia (3.3). Therefore, the changes observed in Eag1 current
density are independent of HIF-1, but dependent on prolyl-hydroxylase activity. No
changes in cellular redox potential is observed after Eag1 expression, indicating that
the prolyl hydroxylases should not act in an unusual way in these cells (3.4).
While no interaction was observed in a yeast 2-hybrid screen between the N-terminus
and any of the PHDs, the C-terminus was found to interact with both PHD1 and PHD3
(3.5, 3.6, 3.7). Interestingly, PHD3 has a much greater affinity for oxygen than its
constituitively expressed cousin PHD2, hydroxylating HIF-1α at lower concentrations
of oxygen. Such an interaction presumably results in proline hydroxylation in Eag1, but
the absence of mass spectrometry analysis prevents us from answering this question.
The poorly-described PHD1 also interacts with Eag1, indicating there may be a novel
role for this otherwise unknown protein.
In contrast, Eag1 also precipitates together with PHD2 (3.9) in vivo, a finding
at odds with the yeast 2-hybrid screen. Moreover, siRNA-mediated knockdown of
PHD2 both reduces high molecular weight Eag1 (??) and reduces Eag1-ubiquitin im-
munoprecipitation (3.15). Finally, block of PHD by DMOG or 1% O2 further reduces
Eag1-ubiquitin immuno-precipitation, an observation that reflects the greater efficacy
of chemical inhibition. Together, these data suggest that PHD2 expression influences
Eag1 ubiquitylation, a finding in contrast to data observed in the yeast-two-hybrid
screen. This conflict between in vitro and in vivo binding results can be reconciled by
recognizing that the in vitro assay is performed using fragments of the Eag1 protein.
75% of the Eag1 protein exists in intracellular domains, many of which are directly
involved in binding soluble proteins in the intracellular space. Moreover, both the N-
(78) and the C-terminus have been identified as important for gating of Eag1 due to
cross-domain interactions between the two termini (79). Expressing only one terminus
could destroy interactions with partners such as PHD2 if this binding depended on
conformational states. That an N- and C-terminus interaction exists suggests that
Eag1 must serve a secondary (and probably tertiary, quarternary, etc) function to the
its canonical role as a conductor of ions, as many much smaller channels function
perfectly well in the absence of large intracellular domains.
One candidate domain for Eag1-PHD interaction is the LXXLAP putative PHD
binding region, just outside the PAS domain on the N-terminus. This motif is highly
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conserved and is critical for recognition of HIF-1α by PHD. Mutants of this motif in
Eag1 show a remarkable change in the normal Eag1 cellular localization (unpublished
data, personally communicated by Dr. Pardo).
The gene egl-9 in Caenorhabditis elegans was also identified as an ortholog of PHD.
The mutant of egl-9 leads to egg-laying deficiency phenotypes (80), a similar phenotype
of which can be obtained by examining mutants of the eag ortholog egl-2 (81). While
similar phenotypes can arise from completely independent causes, a direct relationship
between egl-9 and egl-2 could explain these similarities.
5.2 Eag1 physically and functionally interacts with VHL
While there is no VHL interaction with the N-terminal of Eag1 in vitro (3.10), one
surprising result was the pulldown of Eag1 with VHL in a PHD-independent manner
(3.11). This binding would be expected if the domain of VHL which modifies Eag1
is not the only domain that binds Eag1. For example, binding of VHL to the C-
terminus and gating of Eag1 could swing VHL into position to modify another protein
domain which might normally be inaccessible. VHL and Eag1 co-immunoprecipitate
together in both heterologous and native cells (3.12), indicating an in vivo interaction.
These results are also in good agreement with a description of a functional relationship
between VHL expression and Eag1 current (68).
A VHL interaction would most likely lead to the ubiquitylation of Eag1, as VHL’s
primary role as an E3 ubiquitin ligase is well established (55). Ubiquitin-Eag1 co-
immunoprecipitation is enriched after transfection of VHL cDNA (3.16) and is reduced
after siRNA mediated knockdown of VHL (3.15). The VHL dominant negative mutant
does not have a dramatic influence on Eag1 ubiquitylation, implying that any role for
VHL in Eag1 ubiquitylation is not dependent on the residue that eliminates HIF binding
in VHL. Unfortunately, showing VHL-mediated ubiquitylation in vitro was impossible
due to non-specific antibody recognition (3.17). It seems likely that VHL acts as an
E3-ubiquitin ligase for Eag1, but such a statement cannot be conclusively made.
45
5. DISCUSSION
5.3 Eag1 is ubiquitylated and is proteasomally degraded.
The increase of Eag1 current density and protein (3.19) upon proteasomal block is most
likely related directly to the ubiquitylation of Eag1 (3.13), as ubiquitin is often a degra-
dation signal. MG115 also enriches an Eag1-compatible double band in a S35-labeled
pulse chase degradation assay (3.18). Curiously, blocking PHD activity using DMOG
enhances Eag1 degradation, suggesting that PHD-mediated ubiquitylation does not di-
rect the channel to the proteasome. This could be explained if Eag1 underwent two
regulatory steps in the system I used - an non-specific ERAD pathway associated with
eliminating overexpressed proteins and a more specific PHD-mediated ubiquitylation
system.
Ubiquitylation of ion channels is thought to usually target the protein for internal-
ization and subsequent intracellular targets, often not for the purposes of degradation,
but rather for recycling or modification (for review, see (66)). Ubiquitylation can also
drive transmembrane proteins to be degraded, either by the proteasome or the lyso-
some. The epithelial Na+ channel (ENaC) is enriched both by blockers of the lysosome
and proteasome and by mutants of target lysine residues (82).
The strong enrichment of a 80kDa implies that some part of Eag1 is lysosomally
degraded or targetted for cleavage by a protein that is lysosomally degraded. Because
the antibody used targets the C-terminal of Eag1, this increase can be explained by
several possibilities:
• Cleavage occurs on the N-terminal, cleaving approximately 20kDa from the larger
protein
• Lysosomal block enriches binding of a undescribed binding partner to the C-
terminus of Eag1
• Lysosomal block induces expression of a recently described 80kDa soluble splice
variant implicated in the MAPK and PKA/PKC signalling pathways (83).
Whether this lysosomal effect is related to the proteasomal degradation will be an
interesting question for future experiments.
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5.4 Eag1 stabilizes HIF-1
The very high frequency of ectopic expression of Eag1 in primary tumors (30; 32) indi-
cates that Eag1 expression confers a selective advantage to tumor cells under conditions
that are common to the majority of neoplasms. Such a common condition could be
hypoxia. The major immediate consequence of hypoxia is HIF-1 up-regulation, which
is widely accepted as a hallmark of cancer physiology, both from our understanding of
the tumor micro-environment and the role of HIF-1s target genes in cell proliferation,
survival and angiogenesis (84). The fact that the strongest difference observed in HIF
expression between Eag1 and mock-transfected cells occurs at O2 ranges that are com-
patible with the EC50 of the PHDs (3.25) suggests that this effect is PHD mediated, a
finding which is supported by the interactions between Eag1 and PHD. An even more
compelling argument for the stabilization of HIF being a direct consequence of Eag1
expression would have been found in a rescue of the HIF stabilization upon treatment
with anti-Eag1 siRNA, but the stabilization of HIF by non-targetting siRNA made this
experiment technically difficult (3.26; 3.27).
5.5 Eag1 expression induces VEGF secretion and neo-
angiogenesis
The Eag1-driven increase in VEGF secretion (3.28) and in angiogenesis in vivo (3.30)
provide a likely and novel explanation for the oncogenic potential of Eag1. The ectopic
expression of Eag1 could thus have far reaching effects, as the increased secretion of
growth factors and angiogenic-signaling molecules would have lasting effects within
the local tumor micro-environment. It has been further reported that the related
channel HERG also influences VEGF secretion in glioblastoma cell lines, although the
mechanism by which this occurs remains unclear (85).
5.6 Eag1 may promote tumorigenesis via competitive in-
hibition
Our proposed hypothesis to explain the role of Eag1 in tumorigenesis is that ectopi-
cally expressed Eag1 interacts with prolyl-hydroxylase, sequestering active sites of the
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enzyme that would normally recognize and hydroxylate HIF-1α. Hydroxylated Eag1
would then be recognized by pVHL, further interfering with the normal degradation
pathway of HIF-1α and competing with its ubiquitylation. To support this model, we
provide evidence for direct interactions between Eag1 and three of the four core com-
ponents of the HIF-1a degradation system: pVHL, ubiquitin, and the proteasome. In-
direct evidence presented here shows that the final core component, prolyl hydroxylase,
clearly has some role in modulating Eag1 current density, but difficulties in purifying
transmembrane proteins preclude direct evidence for the hydroxylation of Eag1. This
hypothesis is in good agreement with the report that a tagged destrution domain of
HIF-1α can induce tumorigenic phenotype through competition with HIF-1 for active
sites in pVHL (86).
An alternative model would simply involve physical sequestration of one or more
of the PHDs by Eag1. Such a model has already been proposed for the intracellular
domain (ICD) of Notch and the HIF activity regulator Factor Inhibiting HIF (FIH)
(87). FIH shows a greater affinity for the ICD of Notch than it does for HIF, caus-
ing co-localization of the regulator together with the transmembrane protein. Such
a model could be applied as well to Eag1 and PHD/VHL - the transmembrane pro-
tein preventing regulatory activity simply by virtue of its binding to PHD/VHL. This
binding would most likely also convey some manner of regulatory function onto the
channel. pH dependent sequestration of VHL to the nucleolus has been proposed as
a mechanism to regulate HIF expression (88), demonstrating that simply examining
whether a protein is expressed may obfuscate the full implications of a protein-protein
interaction. (89; 90)
5.7 Eag1 and the brain
While much of this work has been focused on the role of Eag1 in tumorigenesis, these
results have broader implications for the role of Eag1 in the brain. The best character-
ized Eag1-expressing cell line is the neuroblastoma cell line SHSY-5Y. Neuroblastomas
originate from the nervous system, and SHSY-5Y cells can be differentiated upon appli-
cation of retinoic acid into cells indistinguishable from neurons. Upon differentiation,
these cells lose measurable Eag1 current, although that is no indication for the loss
of Eag1 protein (28). Recent reports have identified Eag1 channel localization to the
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somatodendritic region of neurons (89; 90), although unpublished electron microscopy
data refutes that claim (personal communication from Dr. Pardo). In fact, no success-
ful recordings of Eag1 current in neurons have been reported to date, suggesting that
functional Eag1 channels are normally restricted to the synapse.
VHL expression can also induce differentiation in SHSY-5Y cells (60) and differenti-
ation provides protection from hypoxic injury (91). Finally, neurons in PHD3 knockout
mice show reduced apoptosis and impaired development in certain areas of the brain
(92). Given the influence of PHD and VHL on Eag1, it is possible that these effects are
Eag1 mediated, although the influence of HIF on fundamental cellular gene expression
cannot be understated.
Other ion channels and hypoxia have fallen under examination in recent years. The
ATP-sensitive potassium channel KATP has been shown to also serve some protection
from brain hypoxia (93) while hypoxia drives HIF and VHL regulated expression of
Ca2+-activated potassium channels (94).
Oxygen regulation itself is critically important to the proper functioning of the
brain. The brain uses more oxygen than any other organ, utilizing 20% of all oxygen
consumed by the body (95). While the developing brain is resistant to hypoxic insult
(96), neurons deprived of oxygen die within minutes and strokes are one of the leading
causes of death and disability in the developed world. HIF-1 and it’s products EPO
(97) and VEGF (98; 99) have all been implicated in a role of neuroprotection following
hypoxic insult.
5.8 Eag1 likely promotes tumorigenesis via interaction
with intracellular domains
How does Eag1 promote oncogenesis? This is the fundamental question this work seeks
to address, yet in the end this question remains fundamentally unanswered. We know
that Eag1 expression promotes HIF and VEGF expression and increased angiogenesis
in tumors, and that VHL and PHD functionally interact with intracellular domains.
We also know that Eag1 and Eag2 show the greatest dissimilarity in these intracellular
regions, and it has been established that these domains interact with one another.
Unfortunately, we cannot conclude directly with this information that the interaction
between Eag1, PHD, and VHL are sufficient or necessary for tumorigenesis, or that the
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interaction leads to HIF-1 expression. The two observations that Eag1 interacts with
PHD/VHL and Eag1 induces HIF remain, for now, unrelated.
Upon reflection, this finding is not unsurprising - Eag1 is an extremely large protein
with multiple functions and binding sites. Eag1 has now been shown to interact with
CamK2, activated calmodulin, Camguk/CASK adapter protein, PHD, VHL, epsin, and
ubiquitin, in addition to its putative primary role as a conductor of ions. Moreover,
Eag1 expression seems to influence MAPK/mTOR pathways in as of yet undetermined
ways (??,4.2, 4.4). It seems likely that the network of signalling and trafficking path-
ways impacting Eag1 interfere with one another, obfuscating any single pathway’s con-
tribution to Eag1-promoted tumorigenesis. Any interaction between Eag1-promoted
HIF-expression is most likely not the only driver of oncogenesis, but rather is due to a
multitude of factors that influence one another.
Hypotheses to explain how ion channels could contribute to tumor formation have
largely been restricted to analysis of changes in ion permeability, such as changes in cell
volume due to changes in osmotic pressure or the effects of hyper- or de-polarization on
the cell membrane. Yet these speculations have been unable to address the fundamental
question of why only some channel appear to contribute to oncogenesis. Eag1 is an
excellent example of this quandry - it’s close cousin Eag2 is 70% identical and has a
nearly identical electrophysiological profile, yet its expression has not been linked to
any cancer.
Increasingly, binding partners and modulators of Eag1 are being identified, part-
ners whose function in cells regulate the normal cellular mechanisms for controlling
metabolism, cell proliferation, and cell death. These partners represent a novel non-
canonical contribution of an ion channel to tumor formation through pathways at least
partly independent of the putative primary function of Eag1 as an ion channel. While
non-canonical protein functions have been proposed as relevant for the phenotypic
changes induced in heterologous systems (e.g. (100; 101)), the evidence presented here
supports their role in native systems as well. In fact, the primary role of Eag1 may
well be as a voltage sensor, transducing membrane voltage into intracellular signaling,





Cell lines were obtained from DSMZ (Germany) and maintained according to the in-
structions of the provider. For transfected cells, the selection compound Zeocin (Calya)
was added to the culture medium at 3 g/mL. Hypoxia culturing (1% or 3% O2) was
performed by N2 injection in an oxygen-controlling chamber (Labotec). Rapamycin
was obtained from MobiTec.
6.2 Flow Cytometry
Cells were incubated for 20 hours in the absence of selective pressure, washed twice
with cold PBS and fixed for 30 minutes 4% p-formaldehyde at 4 C. Fixed cells were
scraped form the flask and washed 3 times and permeabilized with 0.3% saponin for
15 minutes at room temperature. The cells were then incubated with 10% BSA, 0.15%
saponin for 15 minutes to block non-specific binding, and incubated for 2 hours with
HIF-1α antibody (AB463, BD Biosciences) diluted 1:100 in 0.1% saponin/2% BSA in
PBS (PBS-SB) at 4 C. Cells were washed 3 times with PBS-SB, and then incubated
1.5 hours with a Cy5-conjugated anti-mouse antibody diluted 1:5000 in PBS-SB. Cells
were again washed 3 times and assessed for Cy5 fluorescence using a BD FACSAria
flow cytometer (Becton Dickinson, Heidelberg, Germany) with 633nm laser excitation.
Forward and side scatter were used to detect and discard cell fragments and doublets.
Data are presented as average fluorescence.
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6.3 Electrophysiology
hEag1a-transfected HEK293 and SHSY-5Y neuroblastoma cells were plated on poly-
L-lysine-coated glass coverslips in Petri dishes and allowed to attach overnight. Cells
were then left untreated or treated with some combination of 10 µg/mL cycloheximide
(Sigma), 1mM dimethyoxalylglycine (Frontier Scientific, Europe), or 2mM ascorbate
(Merck) for 6-8 hours. Coverslips were then removed from the dish and used for elec-
trophysiological measurements.
Electrophysiological recordings were performed in the whole cell configuration of
the patch clamp (102) using an EPC9 amplifier and Pulse software (HEKA). Cur-
rents were filtered at 10 KHz and digitized at 50 KHz. Patch pipettes were pulled
from Corning #0010 glass (World Precision Instruments) to resistances of 1-2 M.
Solutions for HEK293 cells contained (mM) Internal: 100 KCl, 45 NMDG, 5 1,1-
bis(O-aminophenoxy)ethane-N,N,N,N-tetracetic acid (BAPTA), 5 EGTA, 1 MgCl2, 10
HEPES ph7.4; external: 160 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 8 Glucose, 10 HEPES,
pH 7.4; for SHSY-5Y, internal: 115 KCl, 1 MgCl2, 5 EGTA, 5 BAPTA, 15 sucrose, ,
10 HEPES pH 7.2 and external: 140 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 8 Glucose, 10
HEPES, pH 7.4.
We used the automated capacity compensation of the amplifier to estimate series
resistance, which was compensated to 85%, and cell capacity. In HEK293 cells, the am-
plitude of the heterologous Eag1 current is robust enough to mask endogenous currents
almost completely (see for example (103)). To determine Eag1 current amplitude, we
applied a conditioning pulse to -100 mV for 1500 ms to slow down the activation of
Eag1, and the outward currents were then elicited by a square depolarization to +40
mV for 500 ms. We measured the mean steady state current between 350 and 450 ms
after the start of depolarization and subtracted from this value the current amplitude
between 7 and 13 ms after the start of depolarization (9).
For measurements of hERG in HEK293 cells, Astemizole (Sigma) or N-Methyl-
Astemizole (? ) were used.
6.4 Transient transfection
Cells to be transfected were first counted using a Neubauer chamber. 1x106 cells
were plated in 6cm petri dishes and cultured for 48 hours to allow cells to firmly
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attach. Lipofectamin 2000 (Invitrogen) and either cDNA or siRNA was incubated in
Optimem per the manufacturer’s direction. Cells were incubated at 37C for 4hrs in
Lipofectamin/nucleic acid mixture, then subjected to a media change. Activity was
assayed 2 days post-transfection.
4mug cDNA was transfected per dish, and 25nM anti-Eag1 siRNA or 50nM of other
siRNA was transfected per dish. PHD2 and PHD3 siRNA sequences are described in
(51), anti-Eag1 siRNA in (22), and anti-HIF and anti-VHL sequences were purchased
from Dharmacon. V5-BACE was obtained from Dr. Christine von Arnim (104) and
VHL, Y98H VHL, PHD2, PHD3, and H196A PHD3 were obtained from Prof. Dr.
Katschinski.
6.5 VEGF ELISA
Mock-transfected, Clone A, Clone B, and Clone C HEK293 cells were counted and
plated at the same density in 25cm2 flasks. Flasks were cultured overnight with medium
containing 3 g/mL Zeocin, then media was changed and cultured for 20 hours without
selection pressure. Cell culture supernatant was removed and centrifuged to remove cell
particulates and detached cells, then assayed for secreted VEGF (Quantikine VEGF
ELISA assay kit, R&D Systems). Cells in the flask were stained with propidium iodide
and counted using a flow cytometer.
6.6 Immunoprecipitation and western blot
At the end of the trestments described in the text, cells were washed twice with PBS,
scraped, centrifuged at 600 xg, and resuspended 3 volumes of lysis buffer (mM: 50 Tris
HCl pH 7.4, 300 NaCl, 5 EDTA, 1% Triton x-100 containing protease inhibitor cocktail
(Roche). After 30 min incubation, cells were centrifuged (14000 xg 15 min) and the
supernatant was used as total cell extract. Protein concentration was determined using
BCA (Pierce).
Immunoprecipitation was achieved by incubation of 500 g of the protein extract with
either 1 g anti VHL (BD Pharmingen) or 2 g anti Eag1 monoclonal antibody mixture.
Immunocomplexes were pulled down using 20 L protein A/G agarose (pre-blocked
with 0.1%BSA). Precipitated agar beads were washed three times with lysis buffer
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containing 0.1% triton and once with PBS. Ubiquitylated proteins were purified using
the Ubiquitinated proteins enrichment kit (Calbiochem), following the manufacturers
protocol.
Protein extracts were separated by gradient SDS-PAGE (either 38 or 412%) and
transferred to nitrocellulose membranes. Membranes were blocked with 0.1% casein
(Roche Applied Science) and incubated with the corresponding antibody. Antibody
against HIF1α(BD Transduction Laboratories) and ubiquitin (P4D1, Cell Signalling)
was used at 0.51 g/ml overnight at 4C in a humidified chamber. Antibody against Eag1
(9391, (105)), V5 (Santa Cruz), VHL (BD Pharmigen) or actin were incubated for 1hr at
room temperature. After washing and incubation with appropriate peroxidase-labeled
secondary antibody, blots were developed using Millipore Immobilon system. Signals
were detected in a Bio-Rad Chem-Doc luminescence detection system.
For HIF1α detection, cells were lysed in 10 mM Tris-HCl pH 6.8, 1% SDS, 5 mM
dithiothreitol, Protease Inhibitor Mixture (Roche Applied Science), and 8 M urea and
to minimize HIF degradation, homogenized using an UltraTurrax device, centrifuged
(14,000 x g 15 min), and the supernatant was used as total cell extract. Protein
concentration was determined using BCA (Pierce).
Eag1-ubiquitin immunopreciptitation was performed as above, but cell lysate was
supplemented with 10mM N-ethylmaleimide (NEM, Sigma) and was stored overnight
at -80 C. After protein concentration determination, lysate was cleared of non-specific
binding using Protein-G conjugated magnetic beads. Lysate was then incubated with
shaking at 4C overnight with 2mug anti-Eag1 monoclonal antibody mixture.
6.7 In vitro transcription-translation (IVTT) and ubiqui-
tylation assay
1.5 µg of hEag1 cDNA was transcribed and translated using Promega TNT T7 IVTT
system per manufacturer’s instructions. A master mix of 50 mM Tris pH7.6, 5mM
MgCl2, 1mM ATP, 0.6 mM DTT, 2.5 µg/µL ubiquitin, 1µM ubiquitin-aldehyde, 20
mM Creatine Phosphate, 0.24 µg/µL Creatine Kinase, and 25µM MG132 was prepared
and diluted to 28:72.
+VHL extracts were treated with .6 ng/uL E1-Ligase, 3.9 ng/µL Ubc3, 3.9 ng/µL




2x106 HEK293 cells were plated in 6cm petri dishes. Cells were washed once with
DMEM media with 10% dialyzed FCS lacking Methionine and Cysteine (starvation
media), then starved for 15 minutes. Dishes were then treated with 10muCi of EasyTag
Express Protein Labeling Mix (Perkin Elmer) for 15 minutes, then washed with warm
PBS and incubated in DMEM/F12 with 10% FCS. Cells to be lysed were washed once
in ice cold PBS with 10mM NEM and lysed as above. SDS-PAGE gels were dryed using
Gel-Dry (Invitrogen) and S35-activity assayed using a Fuji Pictography 3000 detector
6.9 Mouse model
MDA-MB-435S cells (8x106) were implanted into the flank of 8-week-old female scid
mice (Taconic). Treatment started after the tumors reached a size of 2 mm in diameter,
daily via an oral feeder. Body weight and tumor size were measured every 2 days. The
same operator always measured the tumors. Astemizole was prepared as stock solution
(50 mg/ml) in DMSO and diluted in PBS prior to administration. As a positive control,
5mg/kg cyclophosphamide was administered to the animals using the same protocol.
6.10 Luciferase assay
Mock-transfected and Clone A cells were counted and plated at the same density in
6-well plates. Cells were then transfected using Lipofectamine 2000 in Optimem with
Bartons HRE vector for 4 h, after which the medium was changed to normal growth
medium. Luminescence was assayed using a Luciferase Reporter Gene Assay from
Roche Applied Science.
6.11 Inmunohistochemistry
Formalin-fixed and paraffin-embedded tumor sections were deparaffinized and rehy-
drated in a series of xylol and ethanol solutions. Antigen retrieval was performed in
a microwave oven in 10 mM citrate buffer (pH 6.0) for 15 min. Slides were incubated
overnight in a humidified chamber at 4 C with anti CD34, anti VEGF receptor, anti-
Factor VIII (all from Abcam) or anti-CD31 antibodies (Santa Cruz Biotechnology)
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and immunoreactivity was detected using the Envision Peroxidase System and DAB
(DAKO). Sections were counterstained with hematoxylin and thereafter dehydrated
and mounted in xylol-based mounting medium. The quantification of vascular surface
was performed by a blinded operator using ImageJ software on 25 high power fields
(400x) from each sample acquired.
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